| | | 2007 | 72 |
| | | 2021 | 8 |
| | | 8-Jul-2023 | |
| | Zhai, LHuang, CNing, ZZhang, YZhuang, MYang, WWang, XWang, JZhang, LXiao, HZhao, LAsthana, PLam, YYChow, CFWHuang, JDYuan, SChan, KMYuan, CSLau, JYWong, HLXBian, ZX | 11-Jan-2023 | |
| | | 2000 | 97 |
| | | 2011 | 125 |
| | | 2003 | |
| | | 2018 | 45 |
| | | 1998 | 177 |
| | | 1997 | |
| | | 2007 | |
| | Peng, ZhibinWu, PengGe, LiFielding, RichardCheng, XiaowenSu, WeikeYe, MinShi, YingLiao, QiaohongZhou, HangZhou, LeiLi, LeileiWu, JiabingZhang, ShunxiangYu, ZhangdaWu, XiaominMa, HanwuLu, JianhuaCowling, Benjamin J.Yu, Hongjie | 2014 | 85 |
| | | 2022 | |
| | | 2008 | |
| | Zhang, PSun, SLi, NHo, SWAKiang, KMYZhang, XCheng, YPoon, MWLee, DPu, KSJLeung, GKK | 2017 | 99 |
| | | 2015 | 70 |
| RuxolitinibProceeding/Conference:New Drugs Forum 2017, Department of Medicine, the University of Hong Kong | | 2017 | 44 |
| | Zeuser, Rvon Bubnoff, NButler, JMohty, MNiederwieser, DOr, RSzer, JWagner, EMZuckerman, TMahuzier, BXu, JWilke, CGandhi, KKSocie, GThe REACH2 Trial GroupKwong, YL | 2020 | 21 |
| | | 2015 | |
| | | 1991 | |